## Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

**Prescription & Enrollment Form** 

## Fasenra® (benralizumab)



	rour simple ste	eps to submit your referral.		
1 Patient Information	on		copies of front and back of all medical n insurance cards.	
New patient				
Patient's first name		Last name	Middle initial	
Sex at birth: Male Female Pron	ouns	Last 4 digits of SSN	Date of birth	
Street address			Apt #	
city	S	tate	Zip	
lome phone	Cell phone	Email add	ress	
'arent/guardian (if applicable)				
lome phone	Cell phone	Email add	ress	
lternate caregiver/contact				
lome phone	Cell phone	Email add	ress	
OK to leave message with alternate	caregiver/contact			
atient's primary language: English	n Other If other, pleas	e specify		
2 Prescriber Inform	ation	All fields must be comp	pleted to expedite prescription fulfillment.	
oate Ti	me	Date medication needed		
office/clinic/institution name				
rescriber info: Prescriber's first name			Last name	
rescriber's title		_ If NP or PA, under direction of	of Dr	
ffice phone	Fax	NPI #	License #	
ffice contact and title		Office con	tact email	
ffice street address			Suite #	
ity	State		Zip	
nfusion location: Patient's home	Prescriber's office Infus	ion site If infusion site, comple	ete information below dotted line:	
nfusion info: Infusion site name		Clinic/hospital affili	ation	
ity		State	Zip	
•		Fax	•	
3 Clinical Informati	on			
CD-10 code (REQUIRED):				
NKDA Known drug allergies				
rior anaphylactic reaction: Yes (Re	eason/date		)	
oncurrent meds				
	ng beta agonist Long-act ne modifiers Oral steroic	ing beta agonist Antihistami ds Nasal steroids Other _	nes Decongestants Immunotherapy	
ab results: History of positive skir	OR RAST test to a perenn	ial aeroallergen		
Pre-treatment serum IgE level	IU per mL Test date.	Pre-treatment se	erum eosinophilscells/mcL and	
putum eosinophils	Date	Patient wt	kg Date wt obtained	
AD Specialty (required): Allergist	Pulmonologist ENT	Primary care Pediatrician	Other	
rescription type: Naïve/new start	Restart Continued th	nerapy		

Dispense as written

Patient's first name	Last name	Middle initial Date of birth
Prescriber's first name	Last name	Phone
4 Prescribing In	formation	
Medication	Strength / Formulation and Directions	Quantity/Refills
Fasenra® (benralizumab) 30mg/mL solution in a single-dose prefilled syringe Fasenra® (benralizumab) 30mg/mL auto-injector pen	Starter Dose: Inject 30mg under the skin every 4 weeks fo 3 doses, followed by once every 8 weeks thereafter.  Maintenance Dose: Inject 30mg under the skin every 8 we	3-month supply
Ι,	Home Authorization for Administration at MDO (excluding Virgin	ealthcare provider for
orefilled syringe be dispensed by	Accredo to the patient's home, but will be administered in o	office or infusion clinic.
Prescriber's signature (sign below	w) (Physician attests this is his/her legal signature. NO STA	AMPS)

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.

Date

Substitution allowed



Date